Outset Medical, Inc. (OM): who owns it and who trades it
As of Nov 16, 2026, OM insiders reported 23 open-market sales worth $369K and 2 purchases worth $870K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Leslie Trigg (CEO), with $122K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Outset Medical
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns OM
92 funds and institutions reported OM shares worth $61.3M at the end of Q2 2026, about 77% of the company. The largest holder is FMR LLC (Fidelity) with 14.8%.
Funds and institutions (13F) 77%Everyone else 23%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 2.74M | 14.80% | $11.8M | No change |
| BML Capital Management, LLC | 2.52M | 13.59% | $10.9M | +32% |
| AQR Capital Management LLC | 998,961 | 5.39% | $4.3M | +24% |
| Perceptive Advisors LLC | 833,333 | 4.50% | $3.6M | No change |
| Vanguard Capital Management LLC | 780,134 | 4.21% | $3.4M | +2% |
| Assenagon Asset Management S.A. | 678,876 | 3.66% | $2.9M | +35% |
| Bank of America Corp | 665,847 | 3.59% | $2.9M | -30% |
| PFM Health Sciences, LP | 582,122 | 3.14% | $2.5M | -2% |
| Ensign Peak Advisors, Inc | 434,341 | 2.34% | $1.9M | -18% |
| BlackRock, Inc. | 418,211 | 2.26% | $1.8M | -67% |
| Peapod Lane Capital LLC | 331,951 | 1.79% | $1.4M | New |
| Marshall Wace, LLP | 211,993 | 1.14% | $916K | New |
| Geode Capital Management, LLC | 204,652 | 1.10% | $885K | -51% |
| Stratos Wealth Partners, LTD. | 200,546 | 1.08% | $866K | No change |
| UBS Group AG | 190,289 | 1.03% | $822K | -25% |
| Morgan Stanley | 181,983 | 0.98% | $786K | +7% |
| Millennium Management LLC | 181,794 | 0.98% | $785K | New |
| Goldman Sachs Group Inc | 173,460 | 0.94% | $749K | +86% |
| Jane Street Group, LLC | 139,197 | 0.75% | $601K | +115% |
| XTX Topco Ltd | 124,690 | 0.67% | $539K | -12% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, OM insiders reported $870K of open-market purchases and $369K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Braden Michael Leonard | 10% owner | Purchase | 16,575 | $3.88 | $64.2K | Form 4 |
| Oct 1, 2026 | Braden Michael Leonard | 10% owner | Purchase | 228,334 | $3.53 | $806K | Form 4 |
| Aug 17, 2026 | Leslie Trigg | CEO | Sale | 3,437 | $4.39 | $15.1K | Form 4 |
| Aug 17, 2026 | John L. Brottem | General Counsel | Sale | 2,632 | $4.39 | $11.6K | Form 4 |
| Aug 17, 2026 | Renee Gaeta | CFO | Sale | 4,543 | $4.39 | $19.9K | Form 4 |
| Jun 3, 2026 | Renee Gaeta | CFO | Sale | 17,672 | $4.94 | $87.3K | Form 4 |
| May 15, 2026 | Leslie Trigg | CEO | Sale | 3,445 | $3.70 | $12.7K | Form 4 |
| May 15, 2026 | Marc Nash | Vice president | Sale | 1,582 | $3.70 | $5.9K | Form 4 |
| May 15, 2026 | John L. Brottem | General Counsel | Sale | 2,638 | $3.70 | $9.8K | Form 4 |
| Feb 17, 2026 | John L. Brottem | General Counsel | Sale | 2,842 | $3.35 | $9.5K | Form 4 |
| Feb 17, 2026 | Leslie Trigg | CEO | Sale | 3,361 | $3.35 | $11.3K | Form 4 |
| Feb 17, 2026 | Marc Nash | Vice president | Sale | 1,817 | $3.35 | $6.1K | Form 4 |
| Jan 21, 2026 | Marc Nash | Vice president | Sale | 980 | $4.98 | $4.9K | Form 4 |
| Jan 21, 2026 | John L. Brottem | General Counsel | Sale | 1,180 | $5.01 | $5.9K | Form 4 |
| Jan 21, 2026 | Leslie Trigg | CEO | Sale | 2,120 | $5.05 | $10.7K | Form 4 |
| Jan 20, 2026 | Marc Nash | Vice president | Sale | 5,375 | $5.12 | $27.5K | Form 4 |
| Jan 20, 2026 | John L. Brottem | General Counsel | Sale | 9,314 | $5.12 | $47.7K | Form 4 |
| Jan 20, 2026 | Leslie Trigg | CEO | Sale | 11,794 | $5.12 | $60.4K | Form 4 |
| Jan 7, 2026 | Marc Nash | Vice president | Sale | 108 | $4.27 | $461 | Form 4 |
| Jan 7, 2026 | John L. Brottem | General Counsel | Sale | 224 | $4.27 | $956 | Form 4 |
| Jan 7, 2026 | Leslie Trigg | CEO | Sale | 1,795 | $4.27 | $7.7K | Form 4 |
| Dec 1, 2025 | Karen Drexler | Director | Sale | 1,548 | $4.37 | $6.8K | Form 4 |
| Nov 17, 2025 | Leslie Trigg | CEO | Sale | 916 | $4.60 | $4.2K | Form 4 |
| Nov 17, 2025 | Marc Nash | Vice president | Sale | 247 | $4.60 | $1.1K | Form 4 |
| Nov 17, 2025 | John L. Brottem | General Counsel | Sale | 388 | $4.60 | $1.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Braden Michael Leonard | 10% owner | $870K | – | Oct 2, 2026 |
| Leslie Trigg | Chair and CEO, Director | – | $122K | Aug 17, 2026 |
| Renee Gaeta | Chief Financial Officer | – | $107K | Aug 17, 2026 |
| John L. Brottem | General Counsel | – | $87.2K | Aug 17, 2026 |
| Marc Nash | EVP Operations R&D & Service | – | $45.9K | May 15, 2026 |
| Karen Drexler | Director | – | $6.8K | Dec 1, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
OM short interest
Low short interest. 4.3% of OM shares are sold short: about 1 share in 23. Over the last 12 reports the number of shares short went down 60%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 812,767 OM shares were sold short, 4.3% of the shares outstanding, down 12.8% from the report before. At the average daily volume of 94,445 shares, buying them all back would take about 8.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 812,767 | 4.32% | -13% | 94,445 | 8.6 |
| Oct 15, 2026 | 932,559 | 4.96% | +18% | 246,119 | 3.8 |
| Sep 30, 2026 | 792,696 | 4.22% | -11% | 133,657 | 5.9 |
| Sep 15, 2026 | 889,575 | 4.73% | -1% | 143,886 | 6.2 |
| Aug 31, 2026 | 901,682 | 4.80% | -4% | 129,027 | 7.0 |
| Aug 14, 2026 | 936,341 | 4.98% | -18% | 156,913 | 6.0 |
| Jul 31, 2026 | 1.14M | 6.16% | -6% | 103,656 | 11.0 |
| Jul 15, 2026 | 1.22M | 6.56% | -19% | 193,746 | 6.3 |
| Jun 30, 2026 | 1.49M | 8.05% | -24% | 456,798 | 3.3 |
| Jun 15, 2026 | 1.97M | 10.63% | -11% | 185,753 | 10.6 |
| May 29, 2026 | 2.22M | 11.99% | +8% | 168,323 | 13.2 |
| May 15, 2026 | 2.05M | 11.08% | +2% | 215,360 | 9.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Outset Medical company events
Outset Medical filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 28, 2026LeadershipJohn Brottem informed Outset Medical, Inc. of his decision to depart from the Company and his role as General Counsel, effective September 11, 2026, to pursue other professional opportunities. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 17, 2026AgreementOutset Medical, Inc., entered into the Refresh Amendment to the Purchasing Agreement with HCA Management Services, L.P., dated May 1, 2020, as amended. Filing
- Jun 5, 2026VoteReported shareholder vote results. Filing
- May 29, 2026LeadershipMarc Nash informed Outset Medical, Inc. of his decision to depart from the Company and his role as Executive Vice President, R&D, Operations and Service, effective June 5, 2026, to pursue other professional opportunities. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Feb 11, 2026ResultsReleased financial results. Filing
- Jan 27, 2026AnnouncementOutset Medical, Inc. announced that the U.S. Food and Drug Administration granted 510(k) clearance for its next-generation Tablo platform, which the Company expects to begin shipping to customers in the second quarter of 2026. Filing
- Jan 12, 2026LeadershipAndrea Saia, a member of the Company’s Board of Directors, stepped down from the Board, effective January 9, 2026. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Outset Medical financials
Famous investors that hold OM
3 of the 50 well-known investors we track reported holding OM in their latest 13F filing. The largest position is Israel Englander's, worth $421K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 140,489 | $421K | 0.0% | -23% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 60,628 | $182K | 0.0% | +40% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 33,566 | $101K | 0.0% | +200% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named OM in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | AQR Capital Management, LLC | 13G/A | 1.8% |
| Nov 13, 2026 | AQR Capital Management, LLC | 13G/A | 1.8% |
| Oct 6, 2026 | BML Investment Partners, L.P. | 13G/A | 14.7% |
| Oct 6, 2026 | BML Investment Partners, L.P. | 13G/A | 14.7% |
Questions about Outset Medical, Inc. (OM) stock
Who owns the most OM stock?
The largest reported owner of Outset Medical, Inc. (OM) is FMR LLC (Fidelity), with 14.8% of the company. In total, 92 funds and institutions reported holding OM at the end of Q2 2026, together about 77% of the shares. See the largest owners.
Are OM insiders buying or selling?
In the last 12 months, OM insiders reported 2 open-market purchases worth $870K and 23 sales worth $369K. The latest trade was on Oct 2, 2026. See every trade.
What is the short interest in OM?
As of Oct 30, 2026, 812,767 OM shares were sold short, 4.3% of the shares outstanding, down 12.8% from the report before. At the average daily volume of 94,445 shares, buying them all back would take about 8.6 trading days (days to cover). See the history.
Which famous investors hold OM?
3 of the 50 well-known investors we track reported OM in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $421K. See all holders.
Executive pay
Outset Medical's chief executive was paid a total of $3.3M for the year ended Dec 31, 2025, down 19% from $4M the year before. In the last 12 months, Outset Medical's executives and directors bought no stock on the open market and sold $369K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.